Click here for more information about Algenuity
Click here for more information about LiqofluxPhenometrics Buy 3 Get 1 Free
Visit cricatalyst.com!Evodos Separation Technology Check out more of The Buzz spacer

Shanghai Green Valley launches brown algae-based Alzheimer’s drug

January 6, 2020
AlgaeIndustryMagazine.com

An extract of brown algae called Oligomannate was approved for clinical trials. Photo: Wright Patterson AFB Courtesy Graphic

Bloomberg News reports that a newly approved Chinese drug for Alzheimer’s will start clinical trials in the U.S. and Europe this year as the country’s first novel therapy for the incurable disease seeks global legitimacy.

Shanghai Green Valley Pharmaceutical Co. (Green Valley) plans to recruit around 2,000 patients with mild-to-moderate Alzheimer’s for trials at 200 sites across North America, Europe and Asia Pacific for 18 months, the company’s Vice President Li Jinhe said.

The drug, an extract of brown algae called Oligomannate, was granted conditional approval in China last month. It comes in a 150mg capsule and went on sale in the country on Dec. 29. Patients will need to take three capsules twice a day, according to the drug’s package insert. A week’s treatment costs 895 yuan (US$128).

Green Valley announced these plans in a press conference in Beijing nearly two months after making global headlines for saying it got approval from China’s regulator for the first new Alzheimer’s drug in 17 years.

The company said it plans to invest $3 billion in the next 10 years for investigations and global trials to understand its working mechanism and expand its use in treating diseases such as Parkinson’s and vascular dementia.

Green Valley plans to file an application for clinical trials with the U.S. Food and Drug Administration in February 2020. It also wants to secure the Fast Track designation, said Green Valley’s Li. This tag helps expedite regulatory review of drugs that treat serious conditions or fill an unmet medical need. The company is also exploring partnerships with global drug makers to speed up clinical trials and help launch the product outside China, Li said.

The Green Valley therapy works differently from the approach taken on Alzheimer’s by western drug developers. Its Oligomannate drug – the name refers to a type of sugar extracted from brown seaweed – is unusual in that it does not target beta amyloid, a protein that forms clumps of plaque in the brain, clogging it in patients with Alzheimer’s.

Oligomannate instead seeks to readjust microbiome in the gut, which ultimately leads to reduced neuron inflammation in the brain and slows the progression of the disease, according to the company.

In Chinese trials, the drug had statistically improved cognitive function in patients suffering from mild-to-moderate Alzheimer’s as early as week four, Green Valley said in a November statement. Its success, however, has been met with skepticism from Alzheimer’s researchers, who say that details are scant on its clinical trials in China.

“Doubts always accompany scientific discovery,” says Geng Meiyu, a researcher with Shanghai Institute of Materia Medica who led the discovery and research of the drug, adding that Green Valley will continue to look into the drug’s working mechanism among humans through further studies and scientific collaboration. “This is just the first step of a long march,” said Geng.

Read More

More Buzz…

Copyright ©2010-2020 AlgaeIndustryMagazine.com. All rights reserved. Permission required to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.

twittertopbarlinks_eventstopbarlinks_requesttopbarlinks_archives

From The A.I.M. Archives

— Refresh Page for More Choices
According to Vegconomist.com, advanced ingredients company Noblegen, creator of proteins, carbohydrates, and oil ingredients from the single celled microorganism Euglena ...
Tavelmout Biofarm (TVMB), a Bruneian subsidiary of Tabérumo Corporation — a pioneer in the large-scale cultivation of spirulina using photobioreactors — has launched thei...
E.A. Crunden writes in thinkprogress.org that Florida’s first gubernatorial debate was dominated by environmental and climate issues, with an emphasis on the state’s alga...
Judith Lewis Mernit writes in e360.yale.edu that an experiment being conducted by animal science professor Ermias Kebreab at the University of California, Davis, is testi...
The Utah Science Technology and Research (USTAR) initiative, a technology-based economic development program funded by the state of Utah, has awarded a $175,320 grant for...
Virginia Tech paleontologists have made a remarkable discovery in China: 1 billion-year-old micro-fossils of green seaweeds that could be related to the ancestor of the e...
Amy Thompson writes in Space.com that SpaceX successfully launched its 15th Space Station cargo-resupply mission on Friday, June 29; carrying a payload of experiments des...
Paris-based Solabia Group (“Solabia”) has acquired Algatech Ltd., a global leader in the development, cultivation and commercialization of ingredients delivered from micr...
Alexander Richter writes in thinkgeoenergy.com that Israel-based Algaennovation last week signed a 15-year contract with Icelandic energy utility and operator ON Power fo...
Baillargues, France’s Microphyt, a leading company in microalgae-based natural solutions for nutrition and well-being, has announced a fundraising of €28.5 million (US$32...
Julianna Photopoulos writes in Horizon EU Research and Innovation magazine that UK start-up Skipping Rocks Lab aims to use natural materials extracted from plants and sea...
Marine ingredient start-up, Yemoja, Ltd., has created a next-gen platform for cultivating customized, pharmaceutical grade microalgae on demand. Founded three years ago b...